Rasmus Holm-Jorgensen - 09 Nov 2022 Form 3 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Chief Financial Officer
Signature
/s/ Rasmus Holm-Jorgensen
Issuer symbol
ACRV
Transactions as of
09 Nov 2022
Net transactions value
$0
Form type
3
Filing time
09 Nov 2022, 19:30:16 UTC
Next filing
16 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ACRV Stock Option (Right to Buy) 09 Nov 2022 Common Stock 192,619 $3.63 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to the option shall vest on April 20, 2023, and the remaining shares subject to the option shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney